Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Ethnicity and prevalence of multiple sclerosis in east London.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
EU regulator warns on possible MS drugs side effects
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Multiple sclerosis in 2014: Progress in MS-classification, mechanisms and treatment.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Mitoxantrone: benefits and risks in multiple sclerosis patients.
Current and future immunotherapy targets in autoimmune neurology.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma.
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
Headache in relapse and remission phases of multiple sclerosis: A case-control study.

Pages